GALT vs SVRA
GALT: Clinical-stage biopharmaceutical company developing galectin-3 inhibitors derived from plant carbohydrates to treat liver fibrosis, cirrhosis, and cancer. SVRA: Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
Side-by-side fundamentals
| Metric | GALT | SVRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.50 | $5.65 | |
| Market cap as of 2026-07-23 | $253M | $1.2B | |
| PEG as of 2026-07-23 | n/a | -0.81 | |
| Net margin as of 2026-07-23 | n/a | -4253.9% | |
| Gross margin as of 2026-07-23 | n/a | +100.0% | |
| Operating margin as of 2026-07-23 | n/a | -4150.0% | |
| ROE as of 2026-07-23 | -258.6% | -87.2% | SVRA higher |
| ROA as of 2026-07-23 | -164.7% | -66.4% | SVRA higher |
| Debt / equity as of 2026-07-23 | 11.09 | 0.17 | SVRA lower |
| Beta as of 2026-07-23 | 0.36 | 0.25 | |
| 1-year return as of 2026-07-22 close | +22.4% | +134.4% | SVRA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.